

TO WHOM IT MAY CONCERN

**CONFIRMATION LETTER**

This letter ("**Letter**"), effective as of October 1<sup>st</sup>, 2021 is in reference to the Distribution and Promotion Agreement between **Alcon Pharmaceuticals Ltd.**, located at Rue Louis-d'Affry 6, 1701 Fribourg, Switzerland, ("**APL**") and **NMS ELPA Ltd**, located at 31-22 Malienas Street, LV-1079, Riga, Latvia ("**Distributor**") dated May 1st, 2019, as amended or renewed from time to time ("**Agreement**").

By this Letter, APL hereby confirms that:

1. APL and Alcon Laboratories, Inc., located at 6201 South Freeway, Fort Worth, Texas 76134- 2099 , USA, ("A Icon Laboratories, Inc.") are affiliated companies and part of the Alcon group, i.e. Alcon AG, located at Rue Louis-d' Affry 6, 1701 Fribourg, Switzerland, is the ultimate parent company of APL and Alcon Laboratories, Inc. ;
2. APL is the global distributor of Alcon products in the European Union; and
3. NMS ELPA Ltd located at 31-22 Malienas Street, LV-1079, Riga, Latvia ("**Distributor**") is the non-exclusive distributor of APL and the authorized Technical Service provider in Latvia, Lithuania and Estonia.

Unless otherwise set forth in this Letter, all terms and conditions of the Agreement remain and shall remain in full force and effect.

This Letter shall be effective as of the Effective Date and shall, automatically and without separate notification to third parties, terminate on the earliest of the following occasions:

- (i) October 1<sup>st</sup>, 2022, unless extended by APL in writing;
- (ii) termination or expiration of the Agreement; or
- (iii) revocation of this Letter by APL, at any time and in its sole discretion.

This Letter shall in all respects be subject to, and interpreted in accordance with, the laws of Switzerland.

Sincerely,  
**Alcon Pharmaceuticals Ltd.**



Robert Kamffer  
Authorized Signatory



Pierre Alain Christophe  
Authorized Signatory

**ALCON PHARMACEUTICALS LTD.**  
Rue Louis d'Affry 6  
Case Postale  
1701 Fribourg  
Switzerland